Therapeutic target
Improvement of symptoms by drug control of bleeding disorders (hypermenorrhea, menometrorrhagia) or preoperative reduction of fibroids (benign growths in the muscular layer of the uterus).
Therapy recommendations
- Estrogen-progestin monophasic preparations, progestin preparations, intrauterine device (“IUD”) with progestin (levonorgestrel) for drug control of bleeding disorders.
- Ulipristal (ulipristal acetate* ; progesterone receptor modulator) for preoperative (“before surgery”) reduction of fibroids Note: There are four case reports of severe liver injury during therapy with ulipristal, three of which required liver transplants.
- See also under “Other Therapy.”
* Note: The EMA Safety Committee is reviewing ulipristal acetate-containing agents used for therapy in uterine fibroids. It recommends discontinuing use of 5 mg ulipristal acetate for treatment in uterine fibroids for the period of the current risk assessment (March 23, 2020).